170 related articles for article (PubMed ID: 16466670)
21. Risperidone liquid in psychotic disorders--efficacy and attitudes.
Jasović-Gasić M; Marić N; Damjanović A
Psychiatr Danub; 2005 Dec; 17(3-4):191-6. PubMed ID: 16392426
[TBL] [Abstract][Full Text] [Related]
22. Little effects of low dosage of levomepromazine on plasma risperidone levels.
Yoshimura R; Shinkai K; Kakihara S; Goto M; Yamada Y; Kaji K; Ueda N; Nakamura J
Pharmacopsychiatry; 2005 Mar; 38(2):98-100. PubMed ID: 15744635
[TBL] [Abstract][Full Text] [Related]
23. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
24. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
25. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
[TBL] [Abstract][Full Text] [Related]
26. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Pérez-Iglesias R; Mata I; Martínez-García O; Garcia-Unzueta MT; Amado JA; Valdizán EM; Vázquez-Barquero JL; Crespo-Facorro B
J Clin Psychopharmacol; 2012 Dec; 32(6):804-8. PubMed ID: 23131886
[TBL] [Abstract][Full Text] [Related]
27. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
Kinon BJ; Gilmore JA; Liu H; Halbreich UM
Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
[TBL] [Abstract][Full Text] [Related]
30. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.
Knegtering R; Baselmans P; Castelein S; Bosker F; Bruggeman R; van den Bosch RJ
Am J Psychiatry; 2005 May; 162(5):1010-2. PubMed ID: 15863810
[TBL] [Abstract][Full Text] [Related]
31. Long-acting risperidone improves negative symptoms in stable psychotic patients.
Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
[TBL] [Abstract][Full Text] [Related]
32. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
33. Gender-specific effects in the treatment of acute schizophrenia with risperidone.
Raedler TJ; Schreiner A; Naber D; Wiedemann K
Pharmacopsychiatry; 2006 Sep; 39(5):171-4. PubMed ID: 16944407
[TBL] [Abstract][Full Text] [Related]
34. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
35. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
36. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Masi G; Cosenza A; Mucci M
J Child Adolesc Psychopharmacol; 2001; 11(4):389-94. PubMed ID: 11838821
[TBL] [Abstract][Full Text] [Related]
37. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
38. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Perez V; Cañas F; Tafalla M;
Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
[TBL] [Abstract][Full Text] [Related]
39. Risperidone long-acting injection in practice - more questions than answers?
Taylor D
Acta Psychiatr Scand; 2006 Jul; 114(1):1-2. PubMed ID: 16774654
[No Abstract] [Full Text] [Related]
40. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
Schmauss M; Sacchetti E; Kahn JP; Medori R
Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
